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Abstract
Human, animal, and in vitro research indicates a beneficial effect of appropriate amounts of omega-
3 (n-3) polyunsaturated fatty acids (PUFA) on bone health. This is the first controlled feeding study
in humans to evaluate the effect of dietary plant-derived n-3 PUFA on bone turnover, assessed by
serum concentrations of N-telopeptides (NTx) and bone-specific alkaline phosphatase (BSAP).
Subjects (n = 23) consumed each diet for 6 weeks in a randomized, 3-period crossover design: 1)
Average American Diet (AAD; [34% total fat, 13% saturated fatty acids (SFA), 13%
monounsaturated fatty acids (MUFA), 9% PUFA (7.7% LA, 0.8% ALA)]), 2) Linoleic Acid Diet (LA;
[37% total fat, 9% SFA, 12% MUFA, 16% PUFA (12.6% LA, 3.6% ALA)]), and 3) α-Linolenic Acid
Diet (ALA; [38% total fat, 8% SFA, 12% MUFA, 17% PUFA (10.5% LA, 6.5% ALA)]). Walnuts and
flaxseed oil were the predominant sources of ALA. NTx levels were significantly lower following
the ALA diet (13.20 ± 1.21 nM BCE), relative to the AAD (15.59 ± 1.21 nM BCE) (p < 0.05). Mean
NTx level following the LA diet was 13.80 ± 1.21 nM BCE. There was no change in levels of BSAP
across the three diets. Concentrations of NTx were positively correlated with the pro-
inflammatory cytokine TNFα for all three diets. The results indicate that plant sources of dietary
n-3 PUFA may have a protective effect on bone metabolism via a decrease in bone resorption in
the presence of consistent levels of bone formation.
Background
Accumulating evidence indicates that dietary fats can
influence bone health. The omega-3 (n-3) polyunsatu-
rated fatty acids (PUFA), in particular, may be beneficial,
as they have been shown to inhibit the activity of osteo-
clasts and enhance the activity of osteoblasts in animals
[1,2]. Optimal quantities of n-3 PUFA, thus, appear to
inhibit bone resorption and promote bone formation. In
addition, the ratio of n-6 to n-3 fatty acids in the diet may
be important. Lowering the dietary ratio of n-6/n-3 PUFA
increased bone marrow cellularity [3] and bone strength
[4] in animals. In contrast, other studies have indicated
that dietary saturated fatty acids (SFA) may adversely
affect bone health. Animal research [5] and epidemiologic
data [6] indicate that diets rich in SFA reduce bone min-
eral density. Possible mechanisms that may account for
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the effects of dietary fatty acids on bone include altera-
tions in prostaglandin production, lipid oxidation, cal-
cium absorption, inflammatory processes and osteoblast
differentiation [2,7-11].
Few studies have evaluated the relationship between die-
tary fats and bone status in humans. Epidemiological
studies have shown inverse relationships between the die-
tary n-6/n-3 ratio and bone mineral density in older
adults [12], as well as between dietary saturated fat and
bone mineral density in men [6]. In contrast, a tendency
toward a positive relationship between eicosapentaenoic
acid (EPA; n-3) consumption and bone density has been
reported [13]. Supplementation trials also indicate posi-
tive effects of n-3 fatty acids on bone health. Twelve
months of EPA supplementation, for instance, increased a
measure of bone density in postmenopausal women [13].
Other studies [14,15] provided oil supplements contain-
ing γ-linolenic acid (GLA) (n-6), EPA and docosahexanoic
acid (DHA) (n-3) to women. When these supplements
were consumed for 16 weeks serum markers indicative of
bone formation increased [16]. When consumed for
longer periods of time, the results were mixed in that n-3/
GLA supplementation increased bone density, compared
to a placebo containing SFA in one study [14]; however,
in the other study, there was no n-3/GLA benefit com-
pared to no supplemental fat [15]. It is likely that the lack
of effect observed by Bassey et al. [15] was due to the large
measurement error associated with total body bone min-
eral density measurements and the shorter study period
(12 vs. 18 mos.). In contrast, the study design employed
by Kruger et al [14] used more specific measures of bone
density (spine and hip bone mineral density scans) to
quantify changes over time.
A lack of effect of n-3 fatty acids on bone health also has
been reported. In a recent study of 179 menopausal
women no change in bone mineral density was observed
following supplementation of 40 g flaxseed/d (9.1 g α-
linolenic acid; ALA) for 12 months [17]. Similarly, in a
randomized controlled trial of chronically inflamed (ele-
vated levels of c-reactive protein) patients with Crohn's
disease, supplementation of 2.7 g/d of EPA and DHA and
antioxidants (vitamins A, C and E and selenium) elicited
no changes in markers of bone resorption and bone for-
mation, despite a significant increase in plasma levels of
EPA, DHA and selenium [18]. Taken together, the epide-
miologic and supplemental feeding data provide some
suggestive evidence that dietary fatty acids, specifically n-
3 fatty acids, can affect bone health in humans. By design,
supplement studies typically do not involve control of the
background diet, and it is possible that differences across
studies could be explained by failure to control for other
nutrients that affect bone. Therefore, controlled feeding
trials are needed in order to convincingly demonstrate a
causal relationship between fatty acids and bone health.
Whereas there are some positive data with marine-derived
n-3 fatty acids, there is little known about the role of
plant-based n-3 fatty acids (ALA) in bone health.
The present investigation is the first controlled feeding
study in humans to evaluate the effect of increasing die-
tary ALA and, thereby, decreasing the ratio of n-6/n-3
PUFA on bone health. Plant sources of ALA (walnuts and
flax) were used. We recently showed that an ALA-rich diet
inhibits vascular inflammation and endothelial activation
in addition to having substantial lipid lowering effects
[19]. A growing body of evidence indicates that many of
the pathophysiological events associated with CVD also
are associated with low bone density. Given the literature
indicating effects of dietary fatty acids on bone health, as
well as reported associations between cardiovascular dis-
ease and low bone density/osteoporosis [20], we sought
to determine if plant-based n-3 PUFA also would be ben-
eficial to bone health.
Subjects and methods
Subjects
The present study was part of a larger study [19] that was
designed to evaluate the effects of dietary fatty acids on
cardiovascular disease risk factors. All twenty-three indi-
viduals (20 males and 3 females) participated in both
studies. Subjects were recruited via advertisements in the
local newspaper and fliers distributed across the campus
of the Pennsylvania State University. Subjects who met
the initial criteria during a phone screen reported to the
Metabolic Diet Study Center (MDSC) for anthropometric
measurements and baseline blood sampling. The Institu-
tional Review Board at the Pennsylvania State University
approved the experimental protocol and all subjects pro-
vided written informed consent.
Baseline subject characteristics are shown in Table 1. Sub-
jects were classified as overweight or obese, i.e., BMI
between 25 and 35 kg/m2. In addition, subjects were
moderately hypercholesterolemic [baseline serum total
cholesterol (TC) between 5.17 and 6.21 mmol/L, LDL-
cholesterol (LDL-C) between 40th and 90th percentiles (by
NHANES III), with HDL-cholesterol (HDL-C) between
25th  and 75th  percentiles (by NHANES III)], and had
serum triglyceride (TG) levels less than 3.95 mmol/L.
Thus, subjects in the present study were quite representa-
tive of the population in the U.S. that is at high risk for car-
diovascular disease. The three females were
postmenopausal, and had not received hormone replace-
ment therapy (HRT) for at least 6 months prior to the start
of the study.Nutrition Journal 2007, 6:2 http://www.nutritionj.com/content/6/1/2
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Study design
A randomized, double-blind, balanced order, three-
period crossover design was employed. A Latin-Square
protocol was used to randomize the subjects into a
sequence of three experimental diets, which differed in
their fatty acid composition. Diet periods lasted 6 weeks
and were separated by an approximate 3-week compli-
ance break during which subjects consumed their usual
diet. The period of time that subjects consumed the diets
(6 weeks) exceeded that for which alterations in serum
NTx and BSAP have been reported in other studies
[21,22].
Subjects consumed either breakfast or dinner at the diet
center on Monday through Friday; all other meals were
prepared and packed for offsite consumption at the sub-
jects' home. Diet compliance was monitored by the staff
of the diet center and by the review of daily and weekly
monitoring forms. Subjects' body weights, usual activities
and exercise levels were maintained throughout the
course of the study.
Experimental diets
Three test diets were used: an average American diet
(AAD) that served as the control diet, and two high-PUFA
diets (low in saturated fat and cholesterol) that had differ-
ent amounts of linoleic acid [LA, C18:2 n-6, (LA Diet)]
and α-linolenic acid [ALA, C18:3 n-3 (ALA Diet)]. For
each of the three experimental diets, eight calorie levels
(1800 – 3900 kcal) were developed to meet different
energy needs of the subjects. Unit foods (muffins) con-
taining the same macronutrient profile of each of the test
diets were used during each diet period to provide incre-
mental adjustments of 100 kcal/day as needed to main-
tain body weight. The nutrient composition of the three
test diets, verified by chemical analyses, is reported in
Table 2. All diets were nutritionally adequate and met 2/3
of the established Dietary Reference Intakes [23]. In addi-
tion, each of the three test diets met or exceeded dietary
recommendations for both ALA and LA [24]. Total fat
(~35% energy), carbohydrate (~50% energy) and protein
(~15% energy) were kept as constant as possible across
the three experimental diets. There were no differences
across the 3 diets for calcium and vitamin D.
The ratio of n-6/n-3 fatty acids for the LA and ALA diets
were 3.5/1 and 1.6/1, respectively. The n-6/n-3 fatty acid
ratio for the AAD was 9/1. The ratios differed primarily
because of a marked increase in ALA in the LA and ALA
diets; the quantity of LA was high for both of these diets
Table 2: Nutritional composition of the three experimental diets (based on 2400 kcal/d); determined from chemical assay
Nutrients AAD LA Diet ALA Diet
CHO* 49.8 46.8 46.3
Protein* 15.7 16.1 16.1
Total Fat* 34.5 37.1 † 37.6 †
SFA* 12.7 8.5 † 8.2 †
MUFA* 13.2 12.2 12.3
PUFA* 8.7 16.4 † 17.2 †
LA* 7.7 12.6 † 10.5 †¶
ALA* 0.8 3.6 † 6.5 †¶
LA/ALA (n-6/n-3) 9.5/1 3.5/1 † 1.6/1 †¶
Cholesterol** (mg/d) 310.8 303.5 305.0
Calcium** (mg) 975.3 1030.9 1016.8
Vitamin D** (μg/IU) 4.704/188.145 4.667/186.708 4.658/186.302
*Values are % energy; **Calculated using Nutritionist V; AAD: Average American Diet
LA Diet: A diet high in PUFA and LA; ALA Diet: A diet high in PUFA and ALA
CHO: Carbohydrate; SFA: Saturated fatty acids; MUFA: Monounsaturated fatty acids;
PUFA: Polyunsaturated fatty acids; LA: Linoleic acid; ALA: α-linolenic acid
†: P < 0.05 compared with AAD for assayed data
¶: P < 0.05 compared with LA Diet for assayed data
Table 1: Subject Characteristics
Men Women All
N2 0 3 2 3
Age (y) 48.6 ± 1.6 58.3 ± 2.7 49.3 ± 1.6
BMI (kg/m2) 28.0 ± 0.7 28.5 ± 2.4 28.1 ± 0.7
Serum Lipids/Lipoproteins
Total Cholesterol (mmol/L) 5.74 ± 0.12 6.58 ± 0.28 5.85 ± 0.12
LDL-Cholesterol (mmol/L) 3.90 ± 0.11 4.53 ± 0.23 3.98 ± 0.11
HDL-Cholesterol (mmol/L) 1.12 ± 0.05 1.36 ± 0.11 1.16 ± 0.04
Triglycerides (mmol/L) 1.55 ± 0.18 1.51 ± 0.29 1.54 ± 0.16Nutrition Journal 2007, 6:2 http://www.nutritionj.com/content/6/1/2
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although it was slightly lower on the ALA diet. Walnuts
and walnut oil, which are particularly rich sources of both
n-6 and n-3 PUFA, represented half of the total fat in the
two high-PUFA diets. The daily consumption of walnuts
and walnut oil was 37 g and 15 g, respectively, for the diet
providing 2400 kcal/day. Sources of walnuts in the diet
included walnut granola, honey walnut butter, walnut
pesto, and plain walnuts as a snack. Flaxseed oil, ~20 g/
day for the 2400 kcal/day diet, also was used to increase
the ALA content of the ALA Diet. Dietary calcium and Vita-
min D levels were calculated using the Nutritionist V data-
base (N-Squared Computing, First DataBank Division,
San Bruno, CA).
Serum samples
Twelve hour fasting blood samples were taken by veni-
puncture on two consecutive days. Whole blood was cen-
trifuged at 3000 rpm for 15 minutes at 4°C. Serum
samples were aliquoted and stored at -80°C until the con-
clusion of the study when all samples were analyzed
together. The serum fatty acid profile was determined
using gas chromatography as described by Zhao et al [19].
In short, serum total lipids were extracted using a chloro-
form:methanol mixture (1:1, v:v) containing BHT
(Sigma) and heptadecanoic acid (used as an internal
standard, Nu-Chek-Prep); serum fatty acid composition
was determined using gas chromatography. Percentage of
individual fatty acids was calculated according to the peak
areas relative to the total area (total fatty acid was set at
100%). Serum N-telopeptides of type I collagen (NTx)
were measured using an enzyme-linked immunosorbent
assay (ELISA) kit (Ostex International, Seattle); the intra-
assay coefficient of variation was 5.5%. Serum NTx is
regarded as a reliable indicator of bone resorption since it
originates from proteolytic cleavage of bone collagen by
osteoclasts, rather than by downstream degradative proc-
esses [25]. Furthermore, measures of serum NTx exhibit
less individual variability than do those of urine [26,27].
Serum bone-specific alkaline phosphatase (BSAP) was
determined using a chemiimmunoluminescent enzy-
matic assay (Quest Diagnostics, Chantilly, VA). BSAP pro-
vides a general index of bone formation, and a specific
index of total osteoblast activity [28]. Serum TNF-α, IL-6,
IL-4 and IL-1β levels were measured using ELISAs in the
Cytokine Core Laboratory of the Pennsylvania State Uni-
versity General Clinical Research Center using protocols
previously described [29].
Statistical analyses
All statistical analyses were performed using SAS for WIN-
DOWS, release 8.2 (SAS Institute, Cary, NC). Data are
expressed as least squares mean ± standard error. Normal-
ity testing was conducted for each outcome variable. The
Kolmogorov-Smirnov test was used to identify 2 individ-
uals whose NTx levels fell outside of the normal distribu-
tion and were classified as outliers. The mixed models
procedure (PROC MIXED) was used to test for effects of
diet, order of diet presentation, period, and their interac-
tions. Tukey-Kramer adjusted P values < 0.05 were used to
determine whether the differences in NTx among diets
were significant. The magnitude and direction of diet
effects were also examined by analyzing change scores
(experimental diets – AAD), with AAD values as covari-
ates. Pearson correlation coefficients were used to evaluate
the relationship between the levels of NTx and the log-
transformed levels of TNFα, IL-6, IL-4, and IL-1β across all
diets. In order to account for the repeated measurement of
outcome variables across three diet periods, an average
correlation for each diet was calculated and the signifi-
cance of this pooled correlation was then tested using a
repeated measures ANOVA with the subject variable as the
repeated measure. All analyses were performed on log-
transformed values; all means reported represent unad-
justed means.
Results
All subjects completed the study (Table 1) and serum fatty
acid analysis (Table 3) revealed excellent dietary compli-
ance [19]. Statistical analyses were first completed with all
subjects (n = 23) and then on all male subjects (n = 20).
Both sets of analyses yielded similar results, thus men and
women were pooled for all analyses presented. Subjects
maintained their baseline body weight throughout the
study. NTx values for one male and one female subject
were classified as significant outliers and excluded from
the analyses, based on the Kolmogorov-Smirnov test. The
final sample size was 21.
Mean NTx concentrations (± SE) at the conclusion of the
three experimental diets were 15.59 ± 1.21, 13.80 ± 1.21,
and 13.20 ± 1.21 nM BCE, for the AAD, LA and ALA diets,
respectively (main effect of diet: p < 0.05). NTx levels were
significantly lower following the ALA diet (p < 0.05) and
there was a similar trend for the LA diet (p = 0.08), com-
pared to the AAD diet (Figure 1). When change scores
were analyzed with the control diet (AAD) NTx levels as a
covariate, both the ALA and LA diets were associated with
significant reductions in NTX concentrations (p < 0.05)
relative to the AAD. The reduction following the ALA diet
was 2.17 ± 0.68 nM BCE (15.3%), while the reduction fol-
lowing the LA diet was 1.77 ± 0.68 nM BCE (11.5%).
Levels of BSAP were unaffected by diet treatment. Mean
concentrations of BSAP at the end of each diet period were
11.78 ± 0.80, 12.41 ± 0.80, and 11.94 ± 0.81 mcg/L, for
the AAD, LA and ALA diets, respectively (p > 0.05). Simi-
larly, the analysis of change scores adjusted for control
diet BSAP showed no significant effects of the interven-
tion diets.Nutrition Journal 2007, 6:2 http://www.nutritionj.com/content/6/1/2
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The effects of these diets on serum cytokine levels are
reported elsewhere [30]. In summary, levels of IL-6, IL-1β
and IL-4 did not change after consumption of the three
test diets. Levels of serum TNFα however were reduced
following the ALA Diet (Median: 10.3 ng/L; Range: (1.2–
12,072.7 ng/L), compared to the LA Diet (Median: 13.3
ng/L; Range: (1.2–1,513.0 ng/L) and the AAD (Median:
18.2 ng/L; Range: (1.2–1,232.5 ng/L) (main effect of diet:
p < 0.08). In subsequent correlational analysis, data from
the 16 individuals with detectable levels of TNFα were
used. The levels of NTx were positively correlated with the
levels of TNF-α(r = 0.54; p < 0.05), across all three diets.
Thus, as TNF-α decreased with increasing intake of n-3
fatty acids, there were proportional decreases in NTx.
Effects of diet on serum fatty acids
The serum fatty acid profile for subjects following the con-
sumption of each of the three test diets is presented in
Table 3. The changes observed in serum fatty acids vali-
date our assessment of dietary compliance with daily and
weekly monitoring forms. As expected, serum total n-6
PUFA were the highest on the LA diet (p < 0.001). Serum
total n-3 PUFA, ALA, and EPA increased progressively
across the LA and ALA diets, with the highest levels on the
ALA diet. The ratios of serum SFA:UNSAT, LA:ALA and n-
6/n-3 decreased significantly following the consumption
of the LA and ALA diets, compared to the AAD (p <
0.001), and following consumption of the ALA diet com-
pared to the LA diet (p < 0.001). There were no significant
correlations between serum concentrations of fatty acids
and BSAP or NTx.
Discussion
This is the first controlled feeding study in humans to
assess the effects of diets rich in ALA and LA provided by
walnuts and flaxseed on bone health, as measured by
serum NTx and BSAP, indicators of bone resorption and
formation, respectively. We found that the high PUFA
diets reduced serum concentrations of NTx, and main-
tained levels of BSAP relative to the consumption of a typ-
ical American diet, which is lower in PUFA and higher in
SFA. NTx after consumption of the ALA diet in particular,
was significantly lower than was NTx after consumption
of the AAD. These effects are consistent with a reduction
in bone turnover and maintenance of bone formation
induced by relatively short-term consumption of the high
PUFA diets. Although the effects of dietary fats on bone
NTx levels when diets differing in fatty acid composition  were consumed Figure 1
NTx levels when diets differing in fatty acid composition 
were consumed. ap < 0.05 when compared to AAD. Vertical 
bars represent the standard errors of the means.
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Table 3: Fatty acid profile (mol %) of serum total lipid in subjects on the three experimental diets (n = 21)
AAD LA Diet ALA Diet
SFA 34.7 ± 0.6 33.0 ± 0.5* 33.5 ± 0.5
MUFA 20.0 ± 0.6 17.0 ± 0.6‡ 17.9 ± 0.6‡
PUFA 45.5 ± 0.7 50.1 ± 0.7‡ 48.7 ± 0.7‡
n-6 PUFA 42.0 ± 0.6 44.9 ± 0.6‡ 42.1 ± 0.6§
LA 33.3 ± 0.5 37.1 ± 0.5‡ 34.6 ± 0.5*§
AA 8.2 ± 0.4 7.5 ± 0.4† 7.3 ± 0.4‡
n-3 PUFA 3.4 ± 0.3 5.2 ± 0.3‡ 6.6 ± 0.3‡§
ALA 0.8 ± 0.2 2.1 ± 0.2‡ 3.1 ± 0.2‡•
EPA 0.5 ± 0.1 0.7 ± 0.1‡ 1.2 ± 0.1‡¶
DPA 0.6 ± 0.04 0.7 ± 0.04 0.7 ± 0.04‡¶
DHA 1.6 ± 0.1 1.7 ± 0.1 1.5 ± 0.1
SFA/UNSAT 0.53 ± 0.01 0.49 ± 0.01† 0.50 ± 0.01*
LA/ALA 49.6 ± 2.3 19.3 ± 2.3‡ 12.4 ± 2.3‡¶
n-6/n-3 12.7 ± 0.5 9.0 ± 0.5‡ 6.8 ± 0.5‡§
SFA: Saturated fatty acids; MUFA: Monounsaturated fatty acids; PUFA: Polyunsaturated fatty acids; n-6: omega-6; LA: Linoleic acid; AA: Arachidonic 
acid; n-3: omega-3; ALA: α-linolenic acid; EPA: Eicosapentaenoic acid; DPA: Docosapentaenoic acid; DHA: Docosahexaenoic acid; UNSAT: total 
unsaturated fatty acids
*: P < 0.05, †: P < 0.01,‡: P < 0.001, compared with AAD
¶ P < 0.05,•: P < 0.01,§ P < 0.001 compared with LA DietNutrition Journal 2007, 6:2 http://www.nutritionj.com/content/6/1/2
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health have been studied in animals and through supple-
mentation in humans, this is the first study to use a whole
food source, incorporated into the diet of humans under
controlled feeding conditions. Previous studies have
shown beneficial effects of walnuts [19,31] and flaxseed
[32] on CVD risk; the present results indicate potential
benefits on bone health, as well.
Some scientists believe that the ratio of dietary n-6/n-3
PUFA is important to a variety of health outcomes [33].
The changes in n-6/n-3 ratios in the present study were
accomplished by increasing the n-3 PUFA, while main-
taining relatively constant levels of n-6 PUFA (Table 2).
NTx levels were significantly lower when subjects con-
sumed the ALA diet (n-6/n-3 ratio: 1.6) than when they
consumed the AAD (n-6/n-3 ratio: 9.5); when subjects
consumed the LA diet (n-6/n-3 ratio: 3.5), NTx levels were
marginally significantly lower than when they consumed
the AAD (p = 0.08). This stepwise reduction in NTx across
the three diets (ALA < LA < AAD) indicates a possible
dose-response effect of dietary n-3 fatty acids and/or
reductions in the n-6/n-3 ratio on bone resorption. The
stepwise nature of the results also indicates that the reduc-
tions in NTx were not due simply to the lower dietary SFA
or the elevated LA in the LA and ALA diets.
The present results do not clearly distinguish if the
observed effects are due to the ALA or to the conversion of
ALA to EPA and its subsequent effects. The majority of
studies investigating the effects of n-3 fatty acids on bone
health have used fish oil, which is rich in EPA. However,
a recent epidemiologic study showed that reduced LA/ALA
ratios were associated with increased hip bone mineral
density [12]. In the present study, plant sources of n-3
fatty acids were used; therefore, ALA was the primary n-3
fatty acid provided by the diet. In addition, the amount of
ALA in the ALA diet (~17 g/day on the 2400 kcal diet) was
greater than that previously provided in a supplementa-
tion trial (~9 g/day) [17]. Both serum ALA and EPA were
significantly greater in the LA and ALA diet conditions
than in the AAD condition. However, serum ALA
increased to a greater degree than did EPA, which reflects
the well established fact that little ALA is converted to EPA
(~5–10%), and little is converted to DHA (< 1%) [34,35].
In the presence of a diet that is relatively high in n-6 PUFA
(such as the LA and ALA diets in the present study), this
conversion is reduced by 40 to 50% [36]. Therefore, it is
possible that in the present study the results are reflective
of an increase in ALA or due to potent effects of EPA. Fur-
ther research is needed to clarify these possibilities.
The reduction in serum NTx that occurred in the present
study following the consumption of the ALA diet for 6
weeks (15.3%) is somewhat less than reports after two
weeks and 1 year of hormone replacement therapy (23%
and 52%, respectively) or after 6 months of alendronate
therapy (30.4%) [37,38]. Whether longer-term intake of
n-3 PUFA would produce larger decreases in NTx and/or
increases in bone density is not known. Regardless, the
present findings confirm and extend a growing literature
indicating beneficial effects of n-3 PUFA and reduced n-6/
n-3 ratios on bone health.
The present results are consistent with animal work in
which appropriate amounts of n-3 PUFA reduced osteo-
clast activity [1]. One mechanism that might account for
this involves local alterations of fatty acid and prostaglan-
din concentrations within bone tissue [8]. Increased con-
sumption of n-6 PUFA increases the ratio of arachidonic
acid (AA) to EPA, and increases PGE2 concentration in
bone [28]. Conversely, an increased consumption of n-3
PUFA decreases the AA:EPA ratio, and decreases PGE2,
concentration and release from bone. This cascade of
effects is potentially important, as PGE2 has been reported
to stimulate bone resorption [see 10 for review]. EPA
serves as a precursor for the formation of PGE3, which also
can stimulate bone resorption. However, the conversion
of EPA to PGE3 is much less efficient than is the conver-
sion of AA to PGE2 [39]. Although measurements of bone
prostaglandins were not taken in the present study, the
serum fatty acid results showed that serum EPA was signif-
icantly greater on the ALA diet than on either the LA diet
or the AAD [19], while AA was significantly reduced. It is
possible that this shift in fatty acid synthesis decreased
production of PGE2 within the bone while having mini-
mal effect on PGE3 formation. The net result would be a
reduction in osteoclast activity and serum NTx concentra-
tions following the ALA diet.
We also examined the relationship between NTx and
cytokines involved in bone remodeling, i.e. tumor necro-
sis factor-alpha (TNFα), IL-6, IL-4, and IL-1B [40,41]. We
previously reported that TNF-α was significantly lower
when the ALA diet was consumed relative to the AAD and
LA diets [30]. In the present study, we showed that TNF-α
levels were correlated with NTx levels across all of the
diets. TNF-α promotes osteoclastic bone resorption and
inhibits bone collagen synthesis in vitro [42], effects that
may be mediated by PGE2 [43]. In addition, TNF-α expres-
sion was enhanced by AA in human osteoblast cells, an
effect that was attenuated by the n-3 fatty acid EPA [44].
Although TNF-α promotes osteoclastogenesis via an auto-
crine mechanism [45], systemic TNF-α also has been
shown to stimulate bone resorption, increase the number
of circulating preosteoclasts [46,47], and elevate plasma
calcium [43]. Furthermore, supplementation with flax-
seed oil, which is a rich in ALA, reduced systemic TNF-α
by about 30% in humans [48], as well as in wild-type and
IL-10 knockout mice [49], and increased bone mineralNutrition Journal 2007, 6:2 http://www.nutritionj.com/content/6/1/2
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content in IL-10 knockout mice [49]. Systemic TNF-α
therefore, may be an important marker of, and/or contrib-
utor to, bone resorptive mechanisms. Taken together, the
present results are consistent with literature indicating
that dietary ALA can reduce bone resorption possibly
through reduced production of TNF-α.
In contrast to the effects of the diets on a marker of bone
resorption, there were no effects on a marker of bone for-
mation (BSAP) in the present study. Although others have
reported that low dietary n-6/n-3 ratios increased BSAP in
developing rats, the present results are consistent with
other negative reports in adults. For instance, no change in
plasma alkaline phosphatase activity was seen in adult
rats maintained on high n-3 diets [50]. In addition, no
change in BSAP occurred when supplements containing a
mixture of n-6 and n-3 fatty acids were given to adult
women [14,15] over an extended period of time (≥ 12
mo), even though bone density increased in one of these
trials [14]. The profile of effects reported here (reduced
NTx, no change in BSAP) is similar to that reported for a
variety of factors affecting bone health including dietary
protein and sodium [51,52], nasal spray calcitonin (after
3 mo) [53], and calcium supplementation [54]. Such a
profile suggests a reduction in bone turnover, and a shift
in the balance of bone degradation/formation toward for-
mation.
In the present study, most of the subjects were middle-
aged men. While this population is generally overlooked
in terms of bone health, the number of men who are
afflicted with osteoporosis continues to grow [55]. Fur-
thermore, recent epidemiologic data suggest that the
effects of dietary fats on bone health may be particularly
strong in men [6]. These reports as well as the present
results indicate that bone health in men bears investiga-
tion, and that bone integrity in men, as well as in women,
may benefit from manipulations of the dietary fatty acid
profile.
In summary, the results of the present study indicate that
incorporating walnuts and flaxseed into the diet as a
means to increase ALA, and consequently decrease the n-
6/n-3 ratio, reduces serum NTx and maintains levels of
serum BSAP. The reductions in NTx were related to the
amount of ALA each diet provided. Omega-3 fatty acids
are known to have beneficial effects on the cardiovascular
system, but few studies have examined their effects on
human bone health. The present results suggest that
incorporating plant sources of n-3 PUFA into the diet may
provide health benefits not only to the cardiovascular sys-
tem, but also to the skeletal system.
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